Valuation: Eli Lilly and Company

Capitalization 885B 763B 689B 661B 1,205B 81,306B 1,261B 8,140B 3,261B 38,991B 3,320B 3,250B 139,447B P/E ratio 2026 *
29.1x
P/E ratio 2027 * 24.7x
Enterprise value 900B 776B 701B 672B 1,226B 82,738B 1,283B 8,284B 3,319B 39,678B 3,379B 3,307B 141,904B EV / Sales 2026 *
11x
EV / Sales 2027 * 9.3x
Free-Float
99.81%
Yield 2026 *
0.67%
Yield 2027 * 0.74%
1 day+0.72%
1 week-5.86%
Current month-5.86%
1 month-6.41%
3 months-1.98%
6 months+36.18%
Current year-7.85%
1 week 965.6
Extreme 965.6
1,056.2
1 month 965.6
Extreme 965.6
1,106.94
Current year 965.6
Extreme 965.6
1,133.95
1 year 623.78
Extreme 623.78
1,133.95
3 years 312.31
Extreme 312.31
1,133.95
5 years 178.58
Extreme 178.5779
1,133.95
10 years 64.18
Extreme 64.18
1,133.95
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2017
Director of Finance/CFO 49 09/09/2024
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 65 01/01/2005
Director/Board Member 69 01/04/2009
Director/Board Member 54 12/12/2011
Change 5d. change 1-year change 3-years change Capi.($)
+0.72%-5.86%+13.89%+218.81% 885B
+0.32%-3.23%+44.22%+56.01% 579B
-0.96%-0.85%+7.38%+50.47% 407B
-2.93%-7.03%+11.14%+27.55% 350B
-1.25%-5.55%+22.14%+55.83% 302B
-1.85%-6.70%+20.11%+33.64% 301B
-0.24%-6.49%+22.33%+4.06% 286B
+0.53%-4.80%+13.75%+61.56% 199B
-0.83%-3.37%+22.59%+79.29% 179B
-0.30%+4.20%-58.52%-51.19% 171B
Average -0.68%-3.80%+11.90%+53.60% 365.97B
Weighted average by Cap. -0.46%-4.18%+16.59%+82.54%

Financials

2026 *2027 *
Net sales 82.11B 70.8B 63.91B 61.32B 112B 7,546B 117B 756B 303B 3,619B 308B 302B 12,942B 94.81B 81.74B 73.79B 70.8B 129B 8,713B 135B 872B 349B 4,178B 356B 348B 14,943B
Net income 30.39B 26.2B 23.65B 22.7B 41.39B 2,793B 43.31B 280B 112B 1,339B 114B 112B 4,790B 36.2B 31.21B 28.18B 27.04B 49.3B 3,327B 51.59B 333B 133B 1,595B 136B 133B 5,706B
Net Debt 15.59B 13.44B 12.13B 11.64B 21.23B 1,433B 22.22B 143B 57.46B 687B 58.5B 57.26B 2,457B -3.14B -2.71B -2.44B -2.34B -4.28B -288B -4.47B -28.88B -11.57B -138B -11.78B -11.53B -495B
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
06/03/26 990.33 $ +0.72% 2,627,805
05/03/26 983.26 $ -2.02% 3,774,397
04/03/26 1,003.57 $ -0.41% 1,965,539
03/03/26 1,007.73 $ -1.01% 2,845,962
02/03/26 1,017.97 $ -3.23% 3,094,287
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
990.33USD
Average target price
1,214.34USD
Spread / Average Target
+22.62%

Quarterly revenue - Rate of surprise